Table 1. Baseline patient characteristics.
Arm A: gemcitabine (n=31) |
Arm B: gemcitabine+200 mg WX-671 (n=31) |
Arm C: gemcitabine+400 mg WX-671 (n=33) |
||||
---|---|---|---|---|---|---|
Patient characteristics | No. | % | No. | % | No. | % |
Gender | ||||||
Male | 14 | 45.2 | 20 | 64.5 | 12 | 36.4 |
Female |
17 |
54.8 |
11 |
35.5 |
21 |
63.6 |
Age, years | ||||||
Median | 59 | 67 | 62 | |||
Range | 48–77 | 48–81 | 39–82 | |||
ECOG performance status | ||||||
0 | 5 | 16.1 | 4 | 12.9 | 8 | 24.0 |
1 |
26 |
83.9 |
27 |
87.1 |
25 |
76.0 |
Tumour localisationa | ||||||
Head | 25 | 80.6 | 28 | 90.3 | 30 | 90.9 |
Body | 5 | 16.1 | 4 | 12.9 | 5 | 15.2 |
Tail | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Periampullary |
1 |
3.2 |
0 |
0.0 |
0 |
0.0 |
T staging | ||||||
T1 | 0 | 0.0 | 0 | 0.0 | 1 | 3.0 |
T2 | 0 | 0.0 | 1 | 3.2 | 1 | 3.0 |
T3 | 11 | 35.5 | 15 | 48.4 | 14 | 42.5 |
T4 | 18 | 58.1 | 15 | 48.4 | 17 | 51.5 |
TX | 2 | 6.5 | 0 | 0.0 | 0 | 0.0 |
More than one localisation possible.